|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | A61K 31/44 | |
| A61P 35/00 | |||
| A61P 35/02 | |||
| A61K 38/18 | |||
| A61K 9/00 | |||
| A61K 31/4745 | |||
| A61K 31/555 | |||
| A61K 31/4375 | |||
| A61K 31/7068 | |||
| A61K 41/00 | |||
| A61K 45/06 | |||
| A61K 47/12 | |||
| C07D 471/04 |
| (11) | Patento numeris | 2295056 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 10177951.0 |
| Europos patento paraiškos padavimo data | 2005-03-14 | |
| (97) | Europos patento paraiškos paskelbimo data | 2011-03-16 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2016-01-06 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (30) | Numeris | Data | Šalis |
| 553578 P | 2004-03-15 | US |
| (72) |
Adelman, Daniel, C., US
Silverman, Jeffrey A., US
MASARU, Higaki, JP
SATOSHI, Nakao, JP
|
| (73) |
Sunesis Pharmaceuticals, Inc.,
395 Oyster Point Blvd., Suite 400, South San Francisco, CA 94080,
US
Sumitomo Dainippon Pharma Co., Ltd., 6-8, Dosho-machi 2-chome Chuo-ku, Osaka-shi Osaka 541-8524, JP |
| (54) | Use of SNS-595 for treating leukemia |
| Use of SNS-595 for treating leukemia |